Physician profile
Kim Burrell
NPI 1053304089
$4,550.89
in general payments reported to CMS, 2019-2025
31 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $49.02 · 2021: $601 · 2022: $1,108 · 2023: $463 · 2024: $769 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.15 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $537.08 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $427.06 | 2023-2025 | Acthar |
| Lumenis Be INC | $395.43 | 2025 | M22 |
| Allergan, INC. | $370.36 | 2019-2022 | |
| Notal Vision, INC. | $314.04 | 2021 | |
| Novartis Pharmaceuticals Corporation | $312.78 | 2019-2023 | |
| Abbvie INC. | $291.90 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $274.89 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $173.41 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Galderma Laboratories, L.P. | $170.63 | 2019-2024 | Dysport |
| Kala Pharmaceuticals, INC. | $166.98 | 2019-2022 | |
| Shire North American Group INC | $142.40 | 2019 | |
| Dompe US, INC. | $141.56 | 2022-2025 | Oxervate |
| Amgen INC. | $133.37 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $116.69 | 2020-2025 | Tryptyr, Eysuvis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $103.56 | 2019-2024 | |
| Thea Pharma INC. | $56.88 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $53.46 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $53.25 | 2023-2025 | Vevye, Iheezo |
| Eyevance Pharmaceuticals LLC | $40.59 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.41 | 2021 | |
| Rxsight INC | $30.95 | 2022 | |
| Horizon Therapeutics Plc | $30.75 | 2022-2023 | Tepezza |
| Astellas Pharma US INC | $28.90 | 2024 | Izervay |
| Mallinckrodt Enterprises LLC | $28.06 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $22.07 | 2021 | |
| Merz North America, INC. | $21.72 | 2022 | |
| Vantage Technology LLC | $18.43 | 2025 | |
| Coopervision INC. | $17.98 | 2022 | |
| Alcon Research LLC | $17.83 | 2019 | |
| Merz Pharmaceuticals, LLC | $17.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Burrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.